<unk>  (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. As of May 2018, the drug is in phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements".
Roluperidone
Domperidone
Ziprasidone
Mepiprazole
Lorpiprazole
Fluparoxan
Chlortalidone
Desmethylclozapine